Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

URGN - UroGen Pharma Ltd.

IEX Last Trade
10.89
0.010   0.092%

Share volume: 4,806
Last Updated: Thu 26 Dec 2024 08:29:51 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$10.88
0.01
0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 8%
Dept financing 2%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.03%
1 Month
-13.30%
3 Months
-15.14%
6 Months
-37.02%
1 Year
-25.07%
2 Year
32.92%
Key data
Stock price
$10.89
P/E Ratio 
0.00
DAY RANGE
$10.60 - $10.89
EPS 
$0.00
52 WEEK RANGE
$10.80 - $20.65
52 WEEK CHANGE
-$28.15
MARKET CAP 
585.807 M
YIELD 
N/A
SHARES OUTSTANDING 
42.114 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$453,214
AVERAGE 30 VOLUME 
$384,915
Company detail
CEO: Elizabeth Barrett
Region: US
Website: urogen.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

UroGen Pharma Ltd. engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs. The company's lead product candidate is UGN-102, which is in Phase III clinical trials.

Recent news